Published in BMC Cancer on July 25, 2015
Minichromosome Maintenance Expression Defines Slow-Growing Gastroenteropancreatic Neuroendocrine Neoplasms. Transl Oncol (2016) 0.75
MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation. Mod Pathol (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol (2009) 9.18
Survival model predictive accuracy and ROC curves. Biometrics (2005) 7.26
Inhibition of eukaryotic DNA replication by geminin binding to Cdt1. Science (2000) 6.48
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol (2010) 5.25
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer (2007) 4.44
Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol (1991) 3.82
Prognostic and predictive factors in early-stage breast cancer. Oncologist (2004) 2.84
MCM proteins: evolution, properties, and role in DNA replication. Biochim Biophys Acta (1998) 2.73
Review: assessment of cell proliferation in histological material. J Clin Pathol (1990) 2.41
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol (2013) 2.28
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat (2011) 1.89
The impact of comorbidity on cancer survival: a review. Clin Epidemiol (2013) 1.68
Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol (2011) 1.57
Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res (2005) 1.50
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol (2011) 1.46
Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. BMC Med Genomics (2008) 1.43
Mouse geminin inhibits not only Cdt1-MCM6 interactions but also a novel intrinsic Cdt1 DNA binding activity. J Biol Chem (2002) 1.43
Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. J Pathol (2004) 1.37
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer (2010) 1.34
Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn Pathol (2012) 1.32
Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat (2009) 1.29
Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis. Neuropathol Appl Neurobiol (2001) 1.28
Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol (2003) 1.24
Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility. Clin Cancer Res (2002) 1.19
Immunohistochemical expressions of Ki-67, cyclin D1, beta-catenin, cyclooxygenase-2, and epidermal growth factor receptor in human colorectal adenoma: a validation study of tissue microarrays. Cancer Epidemiol Biomarkers Prev (2006) 1.04
The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example. J Clin Pathol (2012) 0.97
Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. Acta Oncol (2008) 0.95
Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score. Int J Surg Pathol (2009) 0.88
Use of the St Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy. Br J Surg (2002) 0.87
Quantitative evaluation of protein expression as a function of tissue microarray core diameter: is a large (1.5 mm) core better than a small (0.6 mm) core? Arch Pathol Lab Med (2010) 0.87
The use of digital images improves reproducibility of the ki-67 labeling index as a proliferation marker in breast cancer. Pathol Oncol Res (2013) 0.86
Mcm-2 protein expression predicts prognosis better than Ki-67 antigen in oral cavity squamocellular carcinoma. Anticancer Res (2006) 0.81
[Expression and significance of MCM2, Ki-67 and Rb protein in laryngeal squamous cell carcinomas]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2012) 0.77